Work

Optimizing engineered TCR T cell therapy for synovial sarcoma

Year: 2015

Type: conference-abstract

Abstract: Meeting abstracts Relapsed or metastatic synovial sarcoma remains a significant unmet medical need. NY-ESO-1 is an attractive target for sarcoma, since it is expressed in approximately 70% of synovial sarcomas but not on vital tissues. We generated NY-ESOc259, a human-derived affinity-enhanced T-

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p159

Authors: Sandra D'Angelo, Melinda Merchant, Luca Melchiori, Hua Zhang, Lini Pandite, Tom Holdich, Gwendolyn Binder-Scholl, William Tap, Marylene Fortin, Yoav Peretz, Matthew Wright, Paul Meyers, Rafael Amado, Bent Jakobsen, Crystal Mackall

Institutions: Memorial Sloan Kettering Cancer Center, National Cancer Institute, Adaptimmune (United Kingdom)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2273351973

Cites: 2

Cited by:

Related to: 10